A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who could benefit.

The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...

Hormone therapy has endured a rather bumpy history after the Women’s Health Initiative published clinical trial data in 2002 ...

Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

The FDA approved TherapeuticsMD’s hormone therapy Imvexxy for a vaginal condition linked to low estrogen levels during menopause, the company announced May 30. 1. Imvexxy is intended to treat ...

The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday.

It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide). And, now, it’ll take another three months for the U.S ...

Shares of Ascendis Pharma ASND lost more than 5% on Tuesday after management announced that the FDA extended the review period for its regulatory filing for a hormone replacement therapy by an ...

(Reuters) -The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday. U ...